Loading
Hemostemix Inc. Stock: price and insider trades · Canada
CA·Mcap CA$15.9M
Hemostemix Inc.: what insiders have been doing
Hemostemix Inc. is a listed company. Its insiders report their share dealings to SEDI. The last twelve months, up to 18 October 2026, brought 18 filings signed by 3 insiders.
The flow runs one way only: 1 insider bought (3 purchases totalling €2,514) and nobody sold on the market. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. At €946, the purchase published on 10 August 2026 by Swanberg, Loran Lavern is the largest of the period (0.011% of market cap). The buyers include 1 senior executive.
Compared with its exchange (2,120 companies, median 12 filings), a count of 18 filings is above the norm. Looking back to 2025, when coverage begins, insiders filed 3 purchases and no sales.
The last purchase on record was published on 10 August 2026, which is 68 days ago.
These figures are compiled from regulatory filings published by SEDI. They describe what insiders did and are not a recommendation.
Insider Decl.
19
Thresholds
n/a
Buy Volume
€2,514
3 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleLoran Lavern Swanberg3 buys
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
CA$0.08
Analyst consensus
Income statement
EBITDA-CA$4.3M
Net income-CA$4.7M0.0% margin
Valuation
Beta0.73
Balance sheet & cash
Market capCA$15.9M
Total debtCA$3.6M
Free Cash Flow-CA$4.5M
Profitability & ownership
ROA-534.3%
% insiders16.6%
% institutions0.0%
Last declaration on 10 August 2026
Declarations19 total
1,265,000 shares@ CA$0.0550.49% mcap21.6% of flowCommon SharesTSXSEDI:4762432
1,265,000 shares@ CA$0.0934.9% of flowCommon SharesTSXSEDI:4762422
1,000,000 sharesWarrantsTSXSEDI:4762386
2,000,000 shares@ CA$0.050.69% mcap30.6% of flowCommon SharesTSXSEDI:4762377
22,055 shares@ CA$0.060.0092% mcap0.4% of flowCommon SharesTSXSEDI:4762338
Canonical exit: 8 Sept 2026 (T+90)
625,000 sharesWarrantsTSXSEDI:4762244
26,500 shares@ CA$0.05750.011% mcap0.5% of flowCommon SharesTSXSEDI:4762228
Canonical exit: 8 Sept 2026 (T+90)
400,000 sharesWarrantsTSXSEDI:4762174
400,000 shares@ CA$0.1062.3% of flowCommon SharesTSXSEDI:4762149
290,000 sharesOptionsTSXSEDI:4762043
416,500 sharesOptionsTSXSEDI:4762037
20,000 shares@ CA$0.060.0084% mcap0.4% of flowCommon SharesTSXSEDI:4762030
Canonical exit: 8 Sept 2026 (T+90)
525,000 shares@ CA$0.060.23% mcap12.5% of flowOptionsTSXSEDI:4758019
385,000 shares@ CA$0.060.17% mcap7.1% of flowOptionsTSXSEDI:4757119
1,730,000 sharesOptionsTSXSEDI:4756118
1,000,000 shares@ CA$0.1247.7% of flowWarrantsTSXSEDI:4741236
2,000,000 shares@ CA$0.0539.8% of flowCommon SharesTSXSEDI:4741235
1,500,000 sharesWarrantsTSXSEDI:4599622
100,000 shares@ CA$0.154.6% of flowWarrantsTSXSEDI:4550455
19 of 19 declarations
About Hemostemix Inc.
Hemostemix Inc. is a Toronto Stock Exchange listed company focused on developing regenerative therapies for cardiovascular diseases. It utilizes stem cell-based technologies to enhance patient health.
